Liothyronine sodium
From Wikipedia, the free encyclopedia
| Image:Liothyronine sodium.png | |
|
Liothyronine sodium
|
|
| Systematic (IUPAC) name | |
| 2-amino-3-[4-(4-hydroxy-3-iodo-phenoxy)- 3,5-diiodo-phenyl]-propanoic acid | |
| Identifiers | |
| CAS number | 6893-02-3 |
| ATC code | H03AA02 |
| PubChem | 5920 |
| DrugBank | APRD01074 |
| Chemical data | |
| Formula | C15H12I3NO4 |
| Mol. weight | 650.974 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 99.7% |
| Metabolism | ? |
| Half life | 2.5 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Liothyronine sodium (prepared from triiodothyronine) is a thyroid hormone drug used to treat hypothyroidism. It is a major component of the medication Cytomel ([1], [2]).
[edit] See also
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
